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1. Introduction 
The growth, survival and proliferation of cancer cells are guaranteed by a crosstalk between 
cancer cells themselves and surrounding host cells and extracellular matrix. An intense area 
of research has contributed to a better understanding of the pathophysiological modification 
of tumour progression, e.g., the role of microenvironment.  
Human malignant melanoma is a highly metastatic tumour with poor prognosis and 
extreme resistance to treatment. It progresses through different steps: nevocellular nevi, 
dysplastic nevi (when these two entity can be identified as primary events in melanocytic 
neoplasia progression), in situ melanoma, radial growth phase melanoma (Breslow index 
≤0.75 mm), vertical growth phase melanoma (index >0.75 mm), and metastatic melanoma 
(Breslow, 1970). Primary tumour grows horizontally through the epidermis; over time, a 
vertical growth phase component intervenes and melanoma increases its thickness and 
invades the dermis. Once a vertical growth phase has developed, there is a direct correlation 
between the tumour thickness and the number of metastases (Heasley et al., 1996). 
Parallel with progression, melanoma acquires a rich vascular network. Melanoma 
neovascularization has been correlated with poor prognosis, shorter overall survival, 
ulceration and increased rate of relapse (Srivastava et al., 1988, 1989). This 
neovascularization is initiated and maintained by mean the secretion of various angiogenic 
cytokines, i.e. Vascular Endothelial Growth Factor-A (VEGF-A), Fibroblast Growth Factor-2 
(FGF-2), Placental Growth Factor (PGF) -1 and -2, Interleukin (IL) -8, Transforming Growth 
Factor-1 (TGF-1), by melanoma cells. Moreover cytokines production has been correlated to 
the transition from the radial to the vertical growth phase, and to the metastatic phase 
(Erhard et al., 1997; Marcoval et al., 1997; Salven et al., 1997). 
2. Human melanoma 
Human malignant melanoma originates from the melanocytes and manifests mainly on the 
skin. Rarely, melanomas can occur on the eye, the meninges, and the mucosa in different 
locations. The incidence of melanoma in white populations worldwide is increasing, 
especially in light skinned people with sun exposure. Melanomas are rare in populations 
with pigmented skin and almost always located on the mucosa or the palms of the hands or 
soles of the feet (Garbe et al., 2008).  
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The most important etiological factor for the development of a melanoma is UV radiation. 
Even in childhood, the influence of UV radiation results in the development of benign 
melanocytic neoplasms, in the form of melanocytic nevi. These are indicators of acquired 
mutations in the melanocytic system. The more melanocytic nevi someone has, the higher 
their risk of developing melanoma. Melanomas develop primarily in sites with the highest 
numbers of melanocytic nevi (Garbe et al., 2008). 
Clinically and histologically, four different subtypes of melanoma can be distinguished, 
which have different patterns of mutation: superficially spreading melanoma; nodular 
melanoma; lentigo maligna melanoma; acral lentiginous melanoma. The criteria of the 
ABCDE rule are the main diagnostic criteria (Asymmetry; Border irregularity; Color; 
Diameter; Evolving). Staging (American Joint Committee on Cancer Staging System) is 
important for selecting the best therapeutic approach (Balch et al., 2001, 2009). 
3. Tumour angiogenesis 
Angiogenesis is the sprouting of new blood vessels from a pre-existing vasculature and it is 
a tightly regulated process (Stasi & Amadori, 2002). During embryogenesis two major 
processes of blood vessel formation are implicated in the development of the vascular 
system: vasculogenesis and angiogenesis (Risau, 1988). 
Vasculogenesis starts from mesodermal-derived cells, the hemangioblasts, which 
differentiate both into angioblasts-endothelial cells and into hematopoietic stem cells. 
Vasculogenesis prevails in the embryo but it may have physiological roles in health and 
disease in adults (Iruela-Arispe & Dvorak, 1997). Both mechanisms, angiogenesis and 
vasculogenesis, occur in ischemic and tumour tissues in response to growth factors, such as 
VEGF and FGF-2, produced by tumour and stromal cells (Folkman et al., 2001). In some 
aggressive tumours the vessel wall is lined with only cancer cells as a mosaic of cancer cells 
and endothelial cells. This phenomenon is called “vasculogenesis mimicry” (Dome et al., 
2007).  
Angiogenesis is uncontrolled and unlimited in time, and essential for tumour growth, 
invasion and metastasis during the transition from the avascular to the vascular phase, the 
so-called angiogenic switch, in which the balance between angiogenesis inducers and 
inhibitors leans towards the former. The vascular phase is characterized by the new 
formation of vascular channels that enhance tumour cell proliferation, local invasion, and 
hematogenous metastasis.  
3.1 Angiogenesis and human melanoma 
New blood vessel formation is a prominent feature of human melanomas, indicating that 
these tumours have angiogenic activity (Mihm et al., 1975). The observation that cutaneous 
melanoma cells acquire the capacity to actively induce the growth of new blood vessels 
dates back to the earliest days of tumour angiogenesis research, when Warren and Shubik 
observed it after transplantation of human melanoma fragments into a hamster cheek pouch 
(Warren & Shubik, 1966). These studies were confirmed in later studies (Hubler & Wolf, 
1976). Rapid angiogenesis of cutaneous melanomas dramatically enhances the risk of 
lethality and contributes to the progression of the most common type of young adults (Streit 
& Detmar, 2003). 
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Fig. 1. Processes implied in neovessel formation tumor-induced 
3.1.1 The role of angiogenic cytokines 
Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors 
specific for endothelial cells, able to stimulate the growth of the host’s blood vessels. 
VEGF is expressed in most solid tumours and the VEGF receptors (VEGF-Rs) are 
predominant in endothelial cells surrounding or penetrating malignant tissue, but are 
absent from vascular cells in the surrounding normal tissue. This finding suggests that 
VEGF-Rs expression is induced in endothelial cells during tumour angiogenesis by VEGF 
secreted by tumour cells.  
Secretion of VEGF-A isoform by melanoma cells has been correlated to the transition from 
the radial to the vertical growth phase, and to the metastatic phase (Erhard et al., 1997; 
Marcoval et al., 1997; Salven et al., 1997). Our previous studies indicated that increased 
microvascular density, strong VEGF-A tumour immunoreactivity, increased vascular 
diameter, and high number of vascular pillars—expression of the intussusceptive 
microvascular growth—are correlated to a high Breslow index (>3.6 mm).  
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Fig. 2. Angiogenesis extent parallel with melanoma progression: A) common nevi, B) 
displastic nevi, C) microvessels under the base of melanoma, D) melanoma breslow 0.45 
mm, E) melanoma breslow 1 mm, F) melanoma breslow >3 mm, G) advanced melanoma 
with inflammatory infiltrate, H) bowel metastasis of advanced melanoma 
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Salven et al. (1997) have demonstrated that up-regulation of VEGF-A expression in 
metastatic melanoma is associated with an increase in the number of tumour-infiltrating 
inflammatory cells expressing VEGF-A.  
FGF-2 regulates endothelial cell proliferation and angiogenesis by both autocrine and 
paracrine mechanisms. Since FGF-2 is devoid of the classic signal peptide for secretion, 
tumour cells release this factor by exocytosis from endoplasmic reticulum. Significant 
amounts of FGF-2 were found to be associated with extracellular matrix as well as with 
basement membrane of the newly formed blood vessels in human melanomas. Digestion of 
extracellular matrix by matrix metalloproteinases of melanoma or endothelial origin 
promotes release of matrix bound FGF-2, which, in turn, stimulates endothelial cell 
proliferation and vascular tube formation in melanomas. We and other authors (Salven et 
al., 1997) have demonstrated a significant correlation between melanoma progression, 
percentage of FGF-2-expressing tumour cells, and the number of mast cells which, in turn, 
secrete other angiogenic molecules, such as VEGF-A. 
Another important stimulator of melanoma angiogenesis is PGF. PGF-1 and -2 are expressed 
by melanoma cells and are known to bind neuropilin-1 and -2 receptors expressed on 
endothelial cells (Odorisio et al., 2006). In addition, PGF acts through binding VEGF-R1 
inducing the mobilization and recruitment of VEGF-R1+ hematopoietic precursors from 
bone marrow and enhancing blood vessel maturation by acting on VEGF-R1-expressing 
smooth muscle cells/pericytes (Donnini et al., 1999). Moreover, PGF forms heterodimers 
with VEGF-A and enhances melanoma angiogenesis by activating VEGF-R2 on endothelial 
cells (Donnini et al., 1999; Luttun et al., 2004). 
IL-8 expression was found to be very little in normal epidermis and benign melanocytic 
lesions. However, it is dramatically increased in the majority of cutaneous melanomas. Its 
serum levels in patients are significantly elevated compared to healthy individuals and 
correlate with advanced disease stage as well as with overall survival (Bar-Eli et al., 1999). 
Melanoma-derived IL-8 is able to induce endothelial cell migration, modulate vascular 
permeability, and enhance actin stress fiber formation. These activities resulted in enhanced 
angiogenesis, rapid tumour growth, and increased metastatic potential (Mahler et al., 2004; 
Melnikova & Bar-Eli, 2006). Liu et al. (2005) have demonstrated that TGF-1 is able to 
enhance expression of IL-8 in human melanoma cells and promote angiogenesis in several 
mouse xenograft models. 
Melanotransferrin, a member of the transferrin family, which is comprised of serum 
transferrin, lactoferrin and ovotransferrin, is highly expressed on melanoma cells compared 
to normal melanocytes. It exerts an angiogenic response quantitatively similar to that 
elicidated by FGF-2, and its angiogenic activity may depend on activation of endogenous 
VEGF. We have demonstrated that melanotransferrin contributes to angiogenesis during 
melanoma progression, and is likely associated with VEGF overexpression. 
4. Tumour microenvironment 
Neoplastic cells are influenced by their microenvironment and viceversa. The specific organ 
microenvironment determines the extent of cancer cell proliferation, angiogenesis, invasion 
and survival (Park et al., 2000; Liotta & Kohn, 2001). These data indicate that a permissive 
stromal environment is important in supporting tumour progression in combination with 
genetic alterations.  
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Tumour cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, 
neutrophils, macrophages and mast cells, which communicate via a complex network of 
intercellular signalling pathways, mediated by surface adhesion molecules, cytokines and 
their receptors. 
The inflammatory cell infiltrate, particularly macrophages, may contribute to tumour 
angiogenesis, and there are many reports of associations between macrophage infiltration, 
vascularity and prognosis. Tumour-associated macrophages accumulate in poorly 
vascularized hypoxic or necrotic areas (Leek et al., 1999) and respond to experimental 
hypoxia by increasing the release of VEGF and FGF-2 and a broad range of other factors, 
such as Tumour Necrosis Factor-alpha (TNF-ǂ), urokinase and matrix metalloproteinases 
(Bingle et al., 2002). Moreover, activated macrophages synthesize and release inducible 
nitric oxide synthase, which increases blood flow and promotes angiogenesis (Jenkins et al., 
1995). Lastly, the angiogenic factors secreted by macrophages stimulate mast cell migration 
(Gruber et al., 1995). 
Chemokines also have a role: some CXC chemokines, such as IL-8 are pro-angiogenic 
(Bernardini et al., 2003). Chemokines may exert their regulatory activity on angiogenesis 
directly or as a consequence of leucocyte infiltration and/or the induction of growth factor 
expression. Malignant melanoma is also associated with a dramatic host response composed 
of mast cells at the tumour periphery. 
Mast cells infiltrate hyperplasias, dysplasias and invasive fronts of carcinomas (but not the 
core of solid tumours), where they degranulate in close apposition to capillaries and 
epithelial basement membranes. Mast cells contain many angiogenic factors and a variety of 
cytokines, such as TGF-ǃ, TNF-ǂ, IL-8, FGF-2, VEGF, implicated in normal, as well as 
tumour-associated neoangiogenesis. 
Angiogenesis in human malignant melanoma, measured as microvessel counts, is highly 
correlated with both the percentage of tumour cells reactive to FGF-2 and mast cells counts 
(as total cell and tryptase-positive cell counts), and these parameters increase with tumour 
progression. 
Two distinct types of human mast cells have been described based on the protease 
composition of their secretory granules: mast cells containing chymase, carboxypeptidase, 
cathepsin and tryptase and mast cells containing tryptase only. Tryptase, a protease unique 
to the mast cells secretory granules, acts as a mitogen for fibroblasts, smooth muscle cells, 
and epithelial cells (Brown et al., 1995; Cairns & Walls, 1996). 
Blair and colleagues (Blair et al., 1997) have shown that mast cell-released tryptase plays an 
important role in neovascularization. Tryptase induces the formation of capillary structures 
by either directly acting on endothelial cells or by facilitating the early stages of 
angiogenesis. In fact, tryptase activates latent matrix metalloproteinases and plasminogen 
activator (Stack & Johnson, 1994), which degrade the extracellular matrix, a critical step in 
these stages (Mignatti & Rifkin, 1993). 
Mast cells are strikingly associated with angiogenesis in tumours, namely haemangioma, 
carcinomas, lymphoma and multiple myeloma where they are preferentially accumulated in 
the peripheral areas of the tumour, within the surrounding connective tissue, and rest near 
or around blood or lymphatic vessels. Mast cells are recruited and activated via several 
factors secreted by tumour cells: the c-kit receptor (Norrby & Woolley, 1993), FGF-2, VEGF-
A and Platelet-Derived Endothelial Cell Growth Factor (PD-ECGF), which are operative at 
picomolar concentrations (Gruber et al., 1995). 
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The fact that mast cells contribute to the induction of tumour angiogenesis stems from 
studies on mast cell-deficient mice, which display slow angiogenesis, and its restoration 
after local reconstitution of mast cells (Starkley et al., 1988; Toth et al., 2000). Moreover, in 
malignant breast lesions the number of mast cells with tryptase activity was significantly 
higher than in benign lesions (Kankunnen et al., 1997) and mast cells derived from human 
renal tumour tissues contained tryptase (Beil et al., 1998). 
Tryptase-positive mast cells may contribute, at least partly, to the melanoma-associated 
angiogenesis. Furthermore, tumour-derived FGF-2 may have pleiotropic influences, first on 
tumour invasion, by elevating proteolytic enzymes , second on angiogenesis, by paracrine 
stimulation of endothelial cell growth, and third on recruitment and activation of mast cells, 
which express the FGF-2 receptor. Mast cells, in their turn, secrete FGF-2 stored in their 
secretory granules, which further stimulates endothelial cell growth and amplifies the FGF-2 
paracrine stimulatory loop on angiogenesis. 
4.1 Integrin signalling and extracellular matrix enzymes 
Parallel with the angiogenic switch, an increasing number of tumour cells express the 
laminin receptor, which enables their adhesion to the vascular wall, favouring tumour cell 
extravasation and metastases. Our data indicate that melanoma cells express the 67-kDa 
laminin receptor in step with the progression from the nevocellular to the dysplastic nevi, 
and from the primary to the metastatic tumour. This expression enables melanoma cell 
adhesion to the vascular wall and together with the increased vascular network favours 
tumour cell extravasation and metastasis. 
Overexpression of ǂvǃ3, ǂvǃ5, ǂ2ǃ1, and ǂ5ǃ1 integrins has been correlated with the 
transition from primary to metastatic melanoma (Bosserhoff, 2006). In turn, integrins 
overexpression stimulates matrix metalloproteinases -2 and -7 in melanoma cells, increasing 
their invasive potential (Kuphal et al., 2005). 
Melanoma and tumour stromal cells express several matrix metalloproteinases, including 
matrix metalloproteinases -1, -2, -3, -7, -9, -14, -15, -16, as well as Tissue Inhibitors of Matrix 
Metalloproteinases such as TIMP-1, -2, and -3 (Hofmann et al., 2000a). Matrix metalloproteinases 
overexpression has been correlated with increased microvascular density, Bcl-2 
overexpression, and low survival rate. The most extensively studied matrix metalloproteinases 
in melanomas are the isoforms -2 and -9. 
The expression and activation of both enzymes have been correlated to the invasive and 
metastatic phenotypes of the tumours (Hofmann et al., 2000b; Kerkela & Saarialho-Kere, 
2003; Nikkola et al., 2005; Cotignola et al., 2007; Schnaeker et al., 2004) in which they are 
constitutively expressed and highly associated with atypia and dedifferentiation into 
melanocytic lesions. Matrix metalloproteinase -2 expression was highly correlated with the 
metastatic spread and low survival rates (Hofmann et al., 2000a). Moreover, functional 
activity of matrix metalloproteinases is required for tumour progression. Overexpression of 
Membrane-Type- Matrix Metalloproteinase in melanoma cells induced activation of matrix 
metalloproteinase -2 which is crucial for extracellular matrix degradation. Matrix 
metalloproteinase -2 and Membrane-Type- Matrix Metalloproteinase + tumour cells were 
often restricted to the interface between the tumour invasive part and stroma (Durko et al., 
1997; Hofmann et al., 2000b). 
Expression of matrix metalloproteinases is not restricted to tumour cells but is also found 
abundantly in stromal cells indicating a major contribution of host-derived proteases to 
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tumour progression (Wojtowicz-Praga et al., 1998). Also matrix metalloproteinase -1 
expression is highly associated with melanoma progression (Nikkola et al., 2005). Matrix 
metalloproteinase -9 expression in melanoma cells was found exclusively during the 
horizontal growth phase but not during the vertical phase. This clearly suggests that 
expression of matrix metalloproteinase -9 is an early event in melanoma progression 
(Kerkela & Saarialho-Kere, 2003). 
Several studies using either cell lines or animal models have demonstrated that the balance 
between matrix metalloproteinases and their inhibitors finally determines melanoma 
progression (Hofmann et al., 2000b; Wojtowicz-Praga et al., 1998; Rudek et al., 2001; Jin et 
al., 2006; Wojtowicz-Praga et al., 1996; Bodey et al., 2001; Airola et al., 1999). Overexpression 
of TIMP-1, -2, and -3 significantly reduces melanoma tumour cell invasion, migration, 
growth and metastasis, and significantly reduces tumour neovascularization in several 
tumour models (Anand-Apte et al., 1996). Urokinase Plasminogen Activator and Its Receptor 
(uPA/uPAR) have been demonstrated to play a crucial role in several stages of melanoma 
progression including tumour cell migration, invasion, and metastasis. uPA secreted from 
melanoma cells is able to regulate endothelial cell functions including migration and the 
organization of endothelial cells into tube-like structures (Mueller, 1996; Delbaldo et al., 
1994; Hearing et al., 1988). 
The extracellular matrix enzymes and their inhibitors play also an important role in cancer 
dysregulated angiogenesis (Roy et al., 2009; Huang et al., 2009). These enzymes are the 
major degrading enzymes produced by angiogenic endothelial cells for migration through 
extracellular matrix during neovessel formation. Moreover, matrix metalloproteinases and 
TIMPs may act as regulators of signalling pathways through the cleavage of nonmatrix 
substrates, including cytokines, chemokines, and growth factors. In the last fifteen years, 
different extracellular matrix proteins and cleavage products have been identified. These 
molecules possess the ability to regulate vascular development, repair and function. 
Therefore, possible regulatory mechanisms in vascular biology controlled by different 
cleavage products of basement membrane proteins (e.g., endostatin and tumstatin, 
endorepellin), their activation by proteases and inhibitors, such as matrix metalloproteases, 
cathepsins, tissue inhibitors of matrix metalloproteinases and cystatin, have been reviewed 
in Suhr et al. (2009). 
Integrin-Linked Kinase (ILK) is a highly conserved serine-threonine protein kinase involved in 
cell-extracellular matrix interactions, cytoskeletal organization and cell signalling. 
Overexpression of ILK in epithelial cells leads to anchorage-independent growth with 
increased cell cycle progression. ILK upregulation strongly correlates with melanoma 
progression, invasion and inversely correlates with 5-year survival of melanoma patients 
(Wani et al., 2011). However, the molecular mechanism by which ILK enhances melanoma 
progression is currently unknown. The proangiogenic molecule IL-6 is the downstream 
target of ILK in melanoma cells. Wani et al. (2011) have demonstrated that ILK 
overexpression increases IL-6, whereas silencing of ILK suppressed IL-6 expression at both 
messenger RNA and protein levels. ILK also alteres the activity and subcellular localization 
of Nuclear Factor-KappaB (NF-κB) subunit p65. ILK enhances the IL-6 gene transcription by 
promoting the binding of NF-κB p65 to IL-6 promoter. Moreover, ILK overexpression in 
melanoma cells enhances the tube-forming ability of endothelial cells in vitro and 
microvessel formation in vivo (Wani et al., 2011). 
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
319 
5. Hypoxia in melanoma progression 
Solid tumours, including melanomas, are characterized by areas of hypoxia/anoxia that 
result from an imbalance between oxygen supply and consumption in proliferating tumour 
cells. This imbalance is further exacerbated by a compromised tumour vasculature (Vaupel 
& Mayer, 2007).  
The presence of hypoxia within a tumour is an independent marker of a poor prognosis for 
patients with various cancer types including cutaneous melanomas. Because stringent 
hypoxia/anoxia (<0.5% O2) is toxic for normal and tumour cells, it can promote tumour 
progression by selecting cells with mutations that allow them to survive in these extreme 
conditions. Furthermore, hypoxia activates signalling pathways that trigger 
neovascularization and that facilitate tumour cell invasion, migration, adhesion, and 
metastasis (Bedogni & Broome Powell, 2009). 
Metastasis is a complex multi-step process in which tumour cells have to acquire an 
invasive/migratory phenotype, enter the blood and lymphatic flow, survive anoikis and the 
immune response, and once localized to a distant site, survive in a likely hostile 
environment and proliferate. This process is relatively inefficient and only few cells within a 
tumour mass will have all the requirements that will allow them to successfully metastasize. 
Tumour hypoxia can influence most of the stages of metastasis (Bedogni & Broome Powell, 
2009). 
Hypoxia has been involved in a Epithelial-Mesenchymal Transition-like process where 
tumour cells change from an epithelial non-motile phenotype to a mesenchymal migratory 
phenotype and gain the ability to invade other tissues. Epithelial-Mesenchymal Transition is 
accompanied by specific changes in gene expression, such as down-regulation of E-
cadherin. Tumour hypoxia or loss of von Hippel-Lindau (VHL) which leads to Hypoxia-
Inducible Factor (HIF) stabilization, down-regulates E-cadherin (Yang & Wu, 2008). 
Furthermore, hypoxia through HIF-1, increases invasion by regulating genes, such as matrix 
metalloproteinase-2, that are involved in the degradation and remodelling of the 
extracellular matrix (Krishnamachary et al., 2003).  
Via induction of pro-angiogenic factors such as VEGF, IL-8 and angiopoietin- 2, tumour 
hypoxia contributes to tumour angiogenesis providing cancer cells with access to blood 
vessels which is made easier by the leakiness of the tumour vasculature. HIF-1 can also 
increase resistance to anoikis by down-regulating the expression of ǂ5 integrin which 
mediates survival signals in the presence of extracellular matrix and apoptotic signals when 
cells lack adhesion to a substrate. Finally, by increasing the expression of lysyl oxidase, 
hypoxia/HIF-1 contributes to cancer metastasis in part by facilitating the recruitment of 
bone marrow derived cells to the metastatic niche, which prepares a receptive environment 
for cancer cells (Erler et al., 2009, 2006). 
A direct role of hypoxia in advanced melanoma is slowly starting to emerge. HIF-1 has been 
shown to play a critical role in uveal melanoma progression by increasing the expression of 
a number of target genes involved in invasion. HIF-1 is regarded as one of the critical 
biomarkers that most accurately can predict uveal melanoma metastasis. Furthermore, a 
recent study by Qi et al. (2008), supports a role in melanomagenesis and metastasis of Siah2. 
Siah2, recently found to be regulated by the Serine/Threonine Protein Kinase Akt, is an 
inhibitor of Prolyl Hydroxylase Domain Protein function and therefore enhances hypoxia 
dependent HIF-1ǂ stabilization by further inhibiting Prolyl Hydroxylase Domain Protein -1 
and -3 in hypoxia. The authors found that blocking the axis Siah2-Spry2 leads to decreased 
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HIF-1ǂ stabilization, and results in a significant reduction of metastasis in a metastatic 
melanoma mouse model. This observation correlated with findings in human samples 
where reduced expression of the Siah2 substrates Prolyl Hydroxylase Domain Protein-3 and 
Spry2 and increased HIF-1ǂ are characteristic of more advanced melanoma (Bedogni & 
Broome Powell, 2009). 
A role of HIF signalling in melanomagenesis is further supported by the work of 
Giatromanolaki et al. (2003). In this study, HIF-1ǂ and HIF-2ǂ were found to be expressed in 
28 and 65% of melanoma samples respectively, and HIF-2ǂ, together with VEGF and 
vascular density, was associated with poor overall disease survival. 
In summary, these observations strongly support a role of hypoxia and HIF signalling in 
melanomagenesis and melanoma metastasis (Bedogni & Broome Powell, 2009). 
6. Antiangiogenic therapies 
Different molecular targets of antiangiogenic molecules can be recognized, so various 
antiangiogenic agents are currently in clinical trials for melanoma.  
Thalidomide was withdrawn from the market due to its teratogenecity, but in recent years 
its use has been focused on its anti-angiogenic properties (Frankset al., 2004; Kirchmair et al., 
2007; Son et al., 2006). In fact, Thalidomide has been found to have antiangiogenic and anti-
inflammatory properties, and accordingly it has been used as a therapeutic agent in some 
malignant tumours including liver, renal cell, and breast carcinomas (Singhal & Mehta, 
2002).  
We ourselves demonstrated that Thalidomide inhibits many genes which codify for 
angiogenic cytokines and their relative receptors in endothelial cells. Moreover, we have 
demonstrated that Thalidomide reduce the fundamental activity of activated endothelial 
cells (i.e. proliferation, migration, chemotaxis) as well as vessel formation in the Matrigel 
assay. It has been also proposed that the teratogenic property of Thalidomide involves in  
production of Reactive Oxygen Species (ROS), leading to subsequent DNA damage (Maniotis 
et al., 1999). When Thalidomide-induced ROS formation is inhibited, the anti-angiogenesis 
properties of Thalidomide will be reduced. 
Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in 
melanoma through the regulation of vasculogenic factors, and it can induce necrosis of 
tumour cells, which may be related with the NF-kB signalling pathway (Zhang et al., 2008). 
In advanced melanoma Thalidomide has obtained some promising results when used as 
single agent. Pawlak and Legha (Pawlak & Legha, 2004), published a study evaluating 
single-agent Thalidomide in metastatic malignant melanoma, showing no objective 
responses, but seven cases of stable disease.  
Other single agent phase II studies (Reiriz et al., 2004; Eisen et al., 2000) demonstrated stable 
disease in a few patients, with 30% of the patients included in these trials having ocular 
melanoma. In another phase II study Thalidomide has shown limited activity in patients 
with metastatic melanoma against melanoma metastases in the Central Nervous System 
(CNS) (Lene et al., 2008). However, the minor effects founded on peripheral tumour 
manifestations, has led to the conclusion that Thalidomide might be part of the treatment 
strategy for these patients. 
On the basis of these promising but non optimal results and since Thalidomide exhibits low 
oral bioavailability due to limitations in solubility, some experimental modification of oral 
preparation have been tested to improve the delivery of Thalidomide and its therapeutical 
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activity (Kale et al., 2008). Its complexation with sulfobutyl ether-7 beta-cyclodextrin has 
demonstrated to increase stability, oral bioavailability, drug absorption, and distribution 
through solubilization of Thalidomide in experimental animals. 
The safety and tolerability of adjuvant treatment with subcutaneous Granulocyte Macrophage 
Colony-Stimulating Factor (GM-CSF) administered in combination with escalating doses of 
Thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high 
risk for recurrence has been also evaluated (Lutzky et al., 2009). This therapy has obtained 
promising results with a 42% overall survival at 2.6 years. However, the high incidence of 
life-threatening events, particularly thrombosis, that are unacceptable in the adjuvant 
setting, render the up-front antithrombotic prophylaxis necessary for further evaluation of 
this combination. 
Many studies are also focused on the effects of Thalidomide on advanced melanoma in 
combination with Interferon alpha 2 b (Hutchins et al., 2007; Vaishampayan et al., 2007), 
Temozolomide (Quirt et al., 2007; Atkins et al., 2008), and Dacarbazine (Ott et al., 2009) with 
encouraging results. The combination of Pegylated Interferon and Thalidomide was 
evaluated in a phase II trial (Vaishampayan et al., 2007). Pegylated Interferon was 
administered at a dose of 0.5 microg/kg subcutaneously weekly and Thalidomide 200 mg 
orally daily. Dose escalation of Thalidomide to 300 mg daily was feasible in some patients. 
This combination was well tolerated but failed to demonstrate clinical efficacy in pretreated 
metastatic melanoma. In fact, no objective responses were obtained, and only three patients 
achieved disease stabilization.  
The addition of Thalidomide to Temozolomide with or without whole brain irradiation does 
not appear to provide a substantial advantage in the treatment of patients with CNS 
metastasis from melanoma but seems to add only toxicity. An initial study (Hwu et al., 2003) 
reported considerable activity (32%response rate) for the Temozolomide and Thalidomide 
combination in the treatment of patients with systemic metastases from melanoma. This 
study combining Temozolomide in the prolonged administration schedule and Thalidomide 
at 200 mg/day with dose escalation to 400 mg/day produced 1 complete response and 11 
partial responses in 38 patients with advanced melanoma and a median survival of 9.5 
months. Evidence of response in CNS metastases was also reported in this setting. 
Subsequent results in a combined 53 evaluable patients in the Cytokine Working Group 
(CWG) and Cancer and Leukemia Group B (CALGB) studies are clearly disappointing (Quirt et 
al., 2007). Fatigue and an increased risk of thromboembolic events, without meaningfully 
increasing the modest CNS antitumour activity previously noted with the Temozolomide 
and whole brain irradiation combination (Margolin et al., 2002) or either Temozolomide 
(Agarwala et al., 2004) or whole brain irradiation alone (Fife et al., 2004). The conclusions of 
this study are consistent with the results of a CALGB trial using a similar regimen (Krown et 
al., 2006). This trial was stopped after 16 patients were enrolled because of excessive toxicity 
that included severe fatigue and sudden death in 1 patient and thromboembolic events 
(pulmonary embolism and deep vein thrombosis) in 4 patients. No tumour responses were 
observed in 14 evaluable patients. 
Given the virtual lack of efficacy observed for the Temozolomide and Thalidomide 
combination against systemic disease in these 2 studies, the lack of significant CNS tumour 
response or major impact on overall survival is not surprising. 
Similar results have been obtained when Thalidomide has been combined with 
Temozolomide alone in patients with stage IV malignant melanoma without active brain 
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metastases (Joseph et al., 2010). In this phase II study patients received Thalidomide 
(200mg/d escalated to 400mg/d for patients <70, or 100mg/d escalated to 250mg/d for 
patients ≥70) plus Temozolomide (75mg/m2/d × 6 weeks then 2 weeks rest). The 
progression free survival was 15% at 6 month and the overall survival was 35% at 1 year. 
Enrolled patients obtained only partial response with a response rate of 13%. Authors 
conclude that this combination of Thalidomide and Temozolomide does not appear to have 
a clinical benefit that exceeds Dacarbazine alone and they not recommend it further for 
phase III trials or for standard community use. 
Similar results have been obtained when Thalidomide has been associated to Dacarbazine in 
the treatment of patients with advanced melanoma (Ott et al., 2009). Of the 13 patients 
evaluable for response of that enrolled in this phase II trial, 1 patient had a partial response, 3 
patients had stable disease and 9 patients had progressive disease. No complete responses 
were achieved. 1 patient withdrew due to toxicity. Grade III/IV constipation, peripheral 
neuropathy, fatigue, edema and rash were attributed to Thalidomide addition. The authors 
conclude that Thalidomide dose escalation beyond 200 mg/day was limited by unacceptable 
toxicity and this combination yielded activity insufficient to proceed with additional trials. 
In the last years Lenalidomide, a less toxic analogue of Thalidomide, has been tested in vitro 
and in vivo. Lenalidomide has been showed good efficacy in hematologic and non 
hematologic cancer with a good toxicity profile (Zeldis et al., 2011). Promising preliminary 
results have been obtained in a study recruit 13 patients with stage IV malignant melanoma 
(Bartlett et al., 2004). Despite the fact that clinical response was not the primary end-point of 
the study and that the patients had not responded to prior therapy, clear evidence of drug 
activity in rapidly progressing malignant melanoma with one partial response and two 
minor responses of visceral disease have been obtained.  
Subsequent studies (Glaspy et al., 2009; Eisen et al., 2010) have demonstrated that treatment 
with Lenalidomide (25 mg/d) has a manageable safety profile in patients with previously 
treated metastatic malignant melanoma. Although no benefit in tumour response, time to 
progression, or overall survival has been achieved in these patients, future trials for 
treatment of metastatic malignant melanoma with Lenalidomide should be conduct which 
focus its use in combination therapies (Lu et al., 2009). 
On the basis of preclinical findings indicating that continuous low dose (metronomic) 
chemotherapy is thought to inhibit tumour angiogenesis, the evaluation of antiangiogenic 
potency of various chemotherapeutic drugs for metronomic chemotherapy, particularly 
Taxol, is ongoing for its efficacy (Drevs et al., 2004). In a pivotal study, 20 patients received 
paclitaxel 10 mg/m2 for 96 hours weekly as a continuous intravenous infusion and oral 
celecoxib 400 mg twice daily. One patient achieved a partial response, and 3 of 20 patients 
(15%) had stable disease for >6 months. The median time to progression was 57 days, and 
the median overall survival was 212 days. These findings support a role for metronomic 
therapy in patients with advanced melanoma. (Bhatt et al., 2010). 
A newest approach to cancer therapy is to target the multicellular biological entity of the 
tumour microenvironment. This type of combination causes an inhospitable 
microenvironment for tumour cells and represent a great promise for clinical use. 
(Blansfield et al., 2008). 
Semaxanib, a small molecule inhibitor of the VEGFR-2 tyrosine kinase, has shown 
encouraging results in patients with metastatic melanoma (Kuenen et al., 2003; Peterson, et 
al., 2004) in whom it has also been evaluated in combination with Thalidomide to assess the 
efficacy, tolerability, pharmacokinetic, and pharmacodynamic characteristics (Mita et al., 
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2007). This last study has demonstrated that the combination Semaxanib-Thalidomide is 
feasible and has also demonstrated antitumour activity in patients with metastatic melanoma 
who had failed prior therapy. Twelve patients were enrolled in this study and received 44 
courses of Semaxanib at the fixed dose of 145 mg/m2 intravenously twice-weekly in 
combination with Thalidomide, commencing at 200 mg daily with intrapatient dose escalation 
as tolerated. The principal toxicities included deep venous thrombosis, headache, and lower 
extremity edema. Out of ten patients evaluable for response, one complete response lasting 20 
months and one partial response lasting 12 months were observed. Additionally, four patients 
had stable disease lasting from 2 to 10 months. These results indicate that the combination of 
Semaxanib and Thalidomide is feasible and demonstrated anti-tumour activity in patients 
with metastatic melanoma who had failed prior therapy.  
Another way to inhibit angiogenesis is the inhibition of matrix metalloproteinase activity. In 
the early 1990, matrix metalloproteinase inhibitors generated great enthusiasm among 
several research groups wishing to take them to clinical trials. Preclinical trials of matrix 
metalloproteinase inhibitors were very promising, showing minimum side effects compared 
to other drugs available at the time. Several current inhibitors, which have been tested in 
preclinical and clinical trials, are broad category matrix metalloproteinase inhibitors. 
Pharmacological inhibitors such as Prinomastat, Batimastat, and its analog Marimastat, 
which interfere with the catalytic site of the matrix metalloproteinases, were the first 
inhibitors studied in detail. Most of the inhibitors tested in clinical trials were not very 
promising due to the lack of positive outcomes and the appearance of substantial drug side 
effects, which were not observed in preclinical studies. Therefore, most of the inhibitor 
clinical trials were terminated following phase 3 clinical trials (Quirt et al., 2002; Pavlaki & 
Zucker, 2003; Coussens et al., 2002).  
Good therapeutic effects have been obtained in little studies with the combination of 
Bevacizumab (the anti-VEGF monoclonal antibody) and chemotherapy in advanced 
melanoma. Moreover, preclinical data strongly support the use of a combination of 
Bevacizumab and Erlotinib, a tyrosine kinase receptors inhibitor (Varker et al., 2007; Perez et 
al., 2009; Vásquez et al., 2009; Schicher et al., 2009). 
PI-88, a potent inhibitor of heparanase, demonstrates an overall survival and time to 
progression similar to standard chemotherapy (Basche et al., 2006). In a phase II trial (Lewis 
et al., 2008) a total of 44 patients were enrolled with about 60% of them previously treated. 
The median time to progression and overall survival was 1.7 months and 9 months, 
respectively. One (2.4%) patient achieved a partial response and six (14.6%) had stable disease 
as best response. At the end of six cycles of treatment, three of the 41 evaluable patients had 
non-progressive disease. Treatment was generally well tolerated with serious bleeding 
occured in two patients and positive anti-platelet antibody test in three patients. One of these 
four patients experienced an associated thrombosis. These results indicate that in patients with 
advanced melanoma, PI-88 demonstrates an overall survival and time to progression similar to 
standard chemotherapy with evidence of activity that warrantee further investigation. 
Preclinical data suggest that the ectopic expression of alphaIIb beta3 in melanoma cells can 
be exploited as a novel target of antibody therapy (Mitjans et al., 2000).  
Although most of these study have obtained encouraging results, further evaluations of 
therapeutic strategies that target multiple angiogenesis pathways may be warranted in 
patients with advanced melanoma and other malignancies. 
Finally, antiangiogenic therapy might have the unintended effect of promoting tumour 
metastasis by increasing vasculogenic mimicry as an alternative circulatory system (Qu et 
al., 2010). When the endothelium-dependent vessels are inhibited by the effective 
angiogenesis inhibitors, the hypoxia of tumour cells caused by antiangiogenesis may 
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increase vasculogenic mimicry compensatively which can replace the job of endothelium-
dependent vessels to maintain the tumour blood supply and provide a convenient route of 
tumour metastasis.  
7. Conclusion 
Tumour microenvironment plays a crucial role in the pathophysiology of human melanoma. 
It is involved in the crosstalk between melanoma cells and the microenvironment cells, 
which increases the survival, proliferation and migration of tumour cells themselves, and 
represents the substrate for angiogenesis which favours disease progression. Due to 
interaction with active microenvironment, neoplastic cells also acquire drug resistance 
giving less opportunity to therapy response. 
Many research studies have tried to better understand the biological mechanisms and the 
genetic basis of all the interactions between tumour cells and the microenvironment cells. 
VEGF, FGF-2, IL-6, IL-8, macrophages, mast cells, and many others cells and molecules, play 
important roles in this process.  
State the important role of angiogenesis in melanoma progression and diffusion, it 
represents a good target for biological therapies. Several molecules targeting the tumour 
microenvironment are actually evaluated in clinical trials and other compounds are in 
preclinical developing. However the initial results obtained with these compounds are 
promising, these approaches should be further developed. 
 
 
Fig. 3. Angiogenesis in human melanoma 
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
325 
8. Acknowledgments 
The Authors would like to thank Prof. Franco Dammacco, Prof. Domenico Ribatti, and Prof. 
Beatrice Nico for their technical support. 
We would also like to thank to Prof. Cecilia Perillo for the English revision of the 
manuscript. 
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), 
Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille n. 9965, 
Milan, Italy. 
9. References 
Agarwala, S.S., Kirkwood, J.M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., 
Buzaid, A., Skarlos, D., & Rankin, E.M. (2004). Temozolomide for the treatment of 
brain metastases associated with metastatic melanoma: a phase II study. J 
ClinOncol., Vol. 22, No., pp. 2101-2107 
Airola, K., Karonen, T., Vaalamo, M., Lehti, K., Lohi, J., Kariniemi, A.L., Keski-Oja, J., & 
Saarialho-Kere, U.K. (1999). Expression of collagenases-1 and -3 and their inhibitors 
TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. British 
Journal of Cancer, Vol.80, No.5-6, pp. 733–743 
Anand-Apte, B., Bao, L., Smith, R., Iwata, K., Olsen, B.R., Zetter, B., & Apte, S.S. (1996). A 
review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental 
analysis of its effect on primary tumour growth. Biochemistry and Cell Biology, Vol. 
74, No.6, pp. 853–862 
Atkins, M.B., Sosman, J.A., Agarwala, S., Logan, T., Clark, J.I., Ernstoff, M.S., Lawson, D., 
Dutcher, J.P., Weiss, G., Curti, B., & Margolin, K.A. (2008). Temozolomide, 
Thalidomide, and whole brain radiation therapy for patients with brain metastasis 
from metastatic melanoma: a phase II cytokine working group study. Cancer, Vol. 
113, No. 8, pp. 2139–2145 
Balch, C.M., Soong, S.J., Gershenwald, J.E., Thompson, J.F., Reintgen, D.S., Cascinelli, N., 
Urist, M., McMasters, K.M., Ross, M.I., Kirkwood, J.M., Atkins, M.B., Thompson, 
J.A., Coit, D.G., Byrd, D., Desmond, R., Zhang, Y., Liu, P.Y., Lyman, G.H., & 
Morabito, A. (2001). Prognostic factors analysis of 17,600 melanoma patients: 
validation of the American Joint Committee on Cancer melanoma staging system. J 
Clin Oncol., (Aug 15 2001), Vol.19, No.16, pp. 3622-34 
Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., Buzaid, 
A.C., Cochran, A.J., Coit, D.G., Ding, S., Eggermont, A.M., Flaherty, K.T., Gimotty, 
P.A., Kirkwood, J.M., McMasters, K.M., Mihm, M.C. Jr, Morton, D.L., Ross, M.I., 
Sober, A.J., & Sondak, V.K. (2009). Final version of 2009 AJCC melanoma staging 
and classification. J Clin Oncol., (Dec 20 2009), Vol.27, No.36, pp. 6199-206 
Bar-Eli, M. (1999). Role of interleukin-8 in tumour growth and metastasis of human 
melanoma. Pathobiology, Vol. 67, No. 1, pp. 12–18 
Bartlett, J.B., Michael, A., Clarke, I.A., Dredge, K., Nicholson, S., Kristeleit, H., Polychronis, 
A., Pandha, H., Muller, G.W., Stirling, D.I., Zeldis, J., & Dalgleish, A.G. (2004). 
Phase I study to determine the safety, tolerability and immunostimulatory activity 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
326 
of Thalidomide analogue CC-5013 in patients with metastatic malignant melanoma 
and other advanced cancers. British Journal of Cancer, No. 90, pp. 955–961 
Basche, M., Gustafson, D.L., Holden, S.N., O'Bryant, C.L., Gore, L., Witta, S., Schultz, M.K., 
Morrow, M., Levin, A., Creese, B.R., Kangas, M., Roberts, K., Nguyen, T., Davis, K., 
Addison, R.S., Moore, J.C., & Eckhardt, S.G. (2006). A phase I biological and 
pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced 
solid tumours, Clinical Cancer Research, Vol. 12, No. 18, pp. 5471–5480  
Bedogni, B., & Broome Powell M. (2009). Hypoxia, melanocytes and melanoma - survival 
and tumour development in the permissive microenvironment of the skin. Pigment 
Cell Melanoma Res, 22(2):166-74 
Beil, W.J., Fureder, W., Wiener, H., Grosschmidt, K., Maier, U., Schedle, A., Bankl, H.C., 
Lechner, K., & Valent, P. (1998). Phenotypic and functional characterization of mast 
cells derived from renal tumour tissues. Exp. Hematol., No. 26, pp. 158–169 
Bernardini, G., Ribatti, D., Spinetti, G., Morbidelli, L., Ziche, M., Santoni, A., Capogrossi, 
M.C., & Napolitano, M. (2003). Analysis of the role chemokines in angiogenesis. J 
Immunol Methods, No. 273, pp. 83–101 
Bhatt, R.S., Merchan, J., Parker, R., HK, Wu., Zhang, L., Seery, V., Heymach, J.V., Atkins, 
M.B., McDermott, D., & Sukhatme, V.P. (2010). A phase 2 pilot trial of low-dose, 
continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with 
metastatic melanoma. Cancer, Vol. 116, No. 7, pp. 1751-6 
Bingle, L., Brown, N.J., & Lewis, C.E. The role of tumour associated macrophages in tumour 
progression: implications for new anticancer therapies. (2002). J Pathol., No. 196, pp. 
254–65  
Blair, R.J., Meng, H., Marchese, M.J., Ren, S., Schwartz, L.B., Tonnesen, M.G., & Gruber, B.L. 
(1997). Human mast cells stimulate vascular tube formation. Tryptase is a novel, 
potent angiogenic factor. J. Clin. Invest., No. 99, pp. 2691–2700 
Blansfield, J.A., Caragacianu, D., Alexander, H.R. 3rd, Tangrea, M.A., Morita, S.Y., Lorang, 
D., Schafer, P., Muller, G., Stirling, D., Royal, R.E., & Libutti, S.K. (2008). Combining 
agents that target the tumour microenvironment improves the efficacy of 
anticancer therapy. Clin Cancer Res, Vol. 14, No. 1, pp. 270-80 
Bodey, B., Gr¨oger, A.M., Siegel, S.E., & Kaiser, H.E. (2001). Invasion and metastasis: the 
expression and significance of matrix metalloproteinases in carcinomas of the lung. 
In Vivo, Vol. 15, No. 2, pp. 175–180 
Bosserhoff, A. K. (2006). Novel biomarkers inmalignant melanoma. Clinica Chimica Acta, Vol. 
367, No. 1-2, pp. 28–35 
Breslow, A. (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of 
cutaneous melanoma. Annals of Surgery, Vol. 172, No. 5, pp. 902–908 
Brown, J.K., Jones, C.A., Tyler, C.L., Ruoss, S.J., Hartmann, T., & Caughey, G.H. (1995). 
Tryptase-induced mitogenesis in airway smooth muscle cells. Chest, No. 107, pp. 
95S–96S  
Cairns, J.A.  & Walls, A.F. (1996). Mast cell tryptase is a mitogen for epithelial cells: 
stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J. 
Immunol., No. 157, pp. 275–283  
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
327 
Clark, J.C., Moon, J., Hutchins, L.F., Sosman, J.A., Kast, W.M., Da Silva, D.M., Liu, P.Y., 
Thompson, J.A., Flaherty, L.E., & Sondak, V.K. (2010). Phase II Trial of 
Combination Thalidomide plus Temozolomide in Patients with Metastatic 
Malignant Melanoma: Southwest Oncology Group S0508. Cancer, Vol. 116, No. 2, 
pp. 424–431 
Cotignola, J., Reva, B., Mitra, N., Ishill, N., Chuai, S., Patel, A., Shah, S., Vanderbeek, G., 
Coit, D., Busam, K., Halpern, A., Houghton, A., Sander, C., Berwick, M., & Orlow, I. 
(2007). Matrix metalloproteinase-9 (MMP-9) polymorphisms in patients with 
cutaneous malignant melanoma. BMC Medical Genetics, Vol. 8, Article 10 
Coussens, L.M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors 
and cancer: trials and tribulations. Science, Vol. 295, No. 5564, pp. 2387–2392  
Delbaldo, C., Masouye, I., Saurat, J.-H., Vassalli, J.-D., & Sappino, A.-P. (1994). Plasminogen 
activation in melanocytic neoplasia. Cancer Research, Vol. 54, No. 16, pp. 4547–4552 
Dome, B., Hendrix, M.J., Paku, S., Tóvári, J., & Tímár, J. (2007). Alternative vascularisation 
mechanisms in cancer: pathology and therapeutic implications. Am J Pathol., No. 
170, pp. 1-15 
Donnini, S., Machein, M. R., Plate, K. H., & Weich, H. A. (1999). Expression and localization 
of placenta growth factor and P1GF receptors in human meningiomas. Journal of 
Pathology, Vol. 189, No. 1, pp. 66–71 
Drevs, J., Fakler, J., Eisele, S., Medinger, M., Bing, G., Esser, N., Marmé, D., & Unger, C. 
(2004). Antiangiogenic potency of various chemotherapeutic drugs for metronomic 
chemotherapy. Anticancer Research, Vol. 24, No. 3A, pp. 1759–1763 
Durko, M., Navab, R., Shibata, H. R., & Brodt, P. (1997). Suppression of basement membrane 
type IV collagen degradation and cell invasion in human melanoma cells 
expressing an antisense RNA for MMP-1. Biochimica et Biophysica Acta, Vol. 1356, 
No. 3, pp. 271–280 
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M.M., Pyle, L., Johnston, S.R., Ahern, 
R., Smith, I.E., & Gore, M.E. (2000). Continuous low dose Thalidomide: A phase II 
study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer., 
Vol. 82, pp. 812-7 
Eisen, T., Trefzer, U., Hamilton, A., Hersey, P., Millward, M., Knight, R.D., Jungnelius, J.U., 
& Glaspy. (2010). J. Results of a Multicenter, Randomized, Double-Blind Phase 2/3 
Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory 
Metastatic Malignant Melanoma. Cancer, No. 116, pp. 146–54 
Erhard, H., Rietveld, F. J. R., van Altena, M. C., Bröcker, E.B., Ruiter, D.J., & de Waal , R.M. 
(1997). Transition of horizontal to vertical growth phase melanoma is accompanied 
by induction of vascular endothelial growth factor expression and angiogenesis, 
Melanoma Research, Vol. 7, No. 2, pp. S19–S26  
Erler, J.T., Bennewith, K.L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.T., Chi, J.T., Jeffrey, 
S.S., & Giaccia, A.J. (2006). Lysyl oxidase is essential for hypoxia-induced 
metastasis. Nature, No. 440, pp. 1222–1226 
Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.T., & Giaccia AJ. 
(2009). Hypoxia induced lysyl oxidase is a critical mediator of bone marrow cell 
recruitment to form the premetastatic niche. Cancer Cell., No. 15, pp. 35–44  
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
328 
Fife, K.M., Colman, M.H., Stevens, G.N., Firth, I.C., Moon, D., Shannon, K.F., Harman, R., 
Petersen-Schaefer, K., Zacest, A.C., Besser, M., Milton, G.W., McCarthy, W.H., & 
Thompson, J.F. (2004). Determinants of outcome in melanoma patients with 
cerebral metastases. J Clin Oncol., Vol. 22, pp. 1293-1300 
Folkman, J., Browder, T., & Palmblad, J. (2001). Angiogenesis research: guidelines for 
translation to clinical application. Thromb Haemost., No. 86, pp. 23-33 
Franks, M.E., Macpherson, G.R., & Figg, W.D. (2004). Thalidomide. Lancet, No. 363, pp. 
1802-1811; 
Garbe, C., Terheyden, P., Keilholz, U., Kölbl, O., & Hauschild, A. (2008). Treatment of 
Melanoma. Dtsch Arztebl Int., Vol. 105, No. 49, pp. 845-51 
Giatromanolaki, A., Sivridis, E., Kouskoukis, C., Gatter, K.C., Harris, A.L., & Koukourakis, 
M.I. (2003). Hypoxia-inducible factors 1alpha and 2alpha are related to vascular 
endothelial growth factor expression and a poorer prognosis in nodular malignant 
melanomas of the skin. Melanoma Res., No. 13, pp. 493–501 
Glaspy, J., Atkins, M.B., Richards, J.M.,  Agarwala, S.S., O’Day, S., Knight, R.D., Jungnelius, 
J.U., & Bedikian, A.Y. (2009). Results of a Multicenter, Randomized, Double-Blind, 
Dose-Evaluating Phase 2/3 Study of Lenalidomide in the Treatment of Metastatic 
Malignant Melanoma. Cancer, No. 115, pp. 5228–36 
Gruber, B.L., Marchase, M.J., & Kaw, R. (1995). Angiogenic factors stimulate mast cell 
migration. Blood, No. 86, pp. 2488–93 
Hearing, V. J., Law, L. W., Corti, A., Appella, E., & Blasi, F. (1988). Modulation of metastatic 
potential by cell surface urokinase of murine melanoma cells. Cancer Research, Vol. 
48, No. 5, pp.1270–1278 
Heasley, D.D., Toda, S., & Mihm Jr., M.C. (1996). Pathology of malignant melanoma. Surgical 
Clinics of North America, Vol. 76, No. 6, pp. 1223–1255 
Hofmann, U.B., Westphal, J.R., Van Muijen, G.N.P., & Ruiter, D.J. (2000a). Matrix 
metalloproteinases in human melanoma. Journal of Investigative Dermatology, Vol. 
115, No. 3, pp. 337–344  
Hofmann, U.B., Westphal, J.R., Zendman, A.J.W., Becker, J.C., Ruiter, D.J., & Van Muijen, 
G.N.P. (2000b). Expression and activation of matrix metalloproteinase-2 (MMP-2) 
and its colocalization with membrane-type I matrix metalloproteinase (MTI-MMP) 
correlate with melanoma progression. Journal of Pathology, Vol. 191, No. 3, pp. 245–
256 
Huang, S.C., Sheu, B.C., Chang, W.C., Cheng, C.Y., Wang, P.H., & Lin, S. (2009). 
Extracellular matrix proteases—cytokine regulation role in cancer and pregnancy. 
Frontiers in Bioscience, Vol. 14, pp. 1571–1588 
Hubler, Jr W., & Wolf, Jr J. (1976). Melanoma. Tumour angiogenesis and human neoplasia. 
Cancer, No. 38, pp. 187-192 
Hutchins, L.F., Moon, J., Clark, J.I., Thompson, J.A., Lange, M.K., Flaherty, L.E., & Sondak, 
V.K. (2007). Evaluation of interferon alpha-2B and Thalidomide in patients with 
disseminated malignant melanoma, phase 2, SWOG 0026. Cancer, Vol. 110, No. 10, 
pp. 2269–2275 
Hwu, W.J., Krown, S.E., Menell, J.H., Panageas, K.S., Merrell, J., Lamb, L.A., Williams, L.J., 
Quinn, C.J., Foster, T., Chapman, P.B., Livingston, P.O., Wolchok, J.D., & 
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
329 
Houghton, A.N. (2003). Phase II study of Temozolomide plus Thalidomide for the 
treatment of metastatic melanoma. J Clin Oncol., Vol. 21, pp.  3351-3356 
Iruela-Arispe, M.L., & Dvorak, H.F. (1997). Angiogenesis: a dynamic balance of stimulators 
and inhibitors. Thromb Haemost., No. 78, pp. 672-677  
Jenkins, D.C., Charles, I.G., Thompson, L.L., Moss, D.W., Holmes, L.S., Baylis, S.A., Rhodes, 
P., Westmore, K., Emson, P.C., & Moncada, S. (1995). Role of nitric oxide in tumour 
growth. Proc Natl Acad Sci USA, No. 92, pp. 4392–6  
Jin, X., Yagi, M., Akiyama, N., Hirosaki, T., Higashi, S., Lin, C.Y., Dickson, R.B., Kitamura, 
H., & Miyazaki, K. (2006). Matriptase activates stromelysin (MMP-3) and promotes 
tumour growth and angiogenesis. Cancer Science, Vol. 97, No. 12, pp. 1327–1334 
Kale, R., Tayade, P., Saraf, M., & Juvekar, A. (2008). Molecular encapsulation of Thalidomide 
with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced 
in vivo antitumour and antiangiogenesis efficacy in mice. Drug Dev Ind Pharm, Vol. 
34, No. 2, pp. 149-56 
Kankunnen, J.P., Harvima, I.T., & Naukkarinen, A. (1997). Quantitative analysis of tryptase 
and chimase containing mast cells in benign and malignant breast lesions. Int. J. 
Cancer, No. 72, pp. 385–388 
Kerkela, E., & Saarialho-Kere, U. (2003). Matrix metalloproteinases in tumour progression: 
focus on basal and squamous cell skin cancer. Experimental Dermatology, Vol. 12, 
No. 2, pp. 109–125 
Kirchmair, R., Tietz, A.B., Panagiotou, E., Walter, D.H., Silver, M., Yoon, Y.S., Schratzberger, 
P., Weber, A., Kusano, K., Weinberg, D.H., Ropper, A.H., Isner, J.M., & Losordo, 
D.W. (2007). Therapeutic angiogenesis inhibits or rescues chemotherapy-induced 
peripheral neuropathy: taxol- and Thalidomide-induced injury of vasa nervorum is 
ameliorated by VEGF. Mol Ther, Vol. 15, No. 1, pp. 69-75 
Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., 
LaRusch, J., Pak, B., Taghavi, P., & Semenza, G.L. (2003). Regulation of colon 
carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res., 63:1138–1143 
Krown, S.E., Niedzwiecki, D., Hwu, W.J., Hodgson, L., Houghton, A.N., & Haluska, F.G. 
(2006). Phase II study of Temozolomide and Thalidomide in patients with 
metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 
500102). Cancer., Vol. 107, pp. 1883-1890 
Kuenen, B.C., Tabernero, J., Baselga, J., Cavalli, F., Pfanner, E., Conte, P.F., Seeber, S., 
Madhusudan, S., Deplanque, G., Huisman, H., Scigalla, P., Hoekman, K., & Harris, 
A.L. (2003). Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single 
agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue 
sarcoma. Clinical Cancer Research, Vol. 9, No. 5, pp. 1648–1655 
Kuphal, S., Bauer, R., & Bosserhoff, A.K. (2005). Integrin signalling in malignant melanoma. 
Cancer and Metastasis Reviews, Vol.24, No. 2, pp. 195–222 
Leek, R.D., Lander, R.J., Harris, A.L., & Lewis, C.E. (1999). Necrosis correlates with high 
vascular density and focal macrophages infiltration in invasive carcinoma of the 
breast. Br J Cancer, No. 79, pp. 991–5  
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
330 
Lene, W., Vestermark, Larsen, S.,  Lindeløv, B., & Bastholt, L. (2008). A phase II study of 
Thalidomide in patients with brain metastases from malignant melanoma. Acta 
Oncologica, Vol. 47, pp. 1526-1530 
Lewis, K.D., Robinson, W.A., Millward, M.J., Powell, A., Price, T.J., Thomson, D.B., Walpole, 
E.T., Haydon, A.M., Creese, B.R., Roberts, K.L., Zalcberg, J.R., & Gonzalez, R. 
(2008). A phase II study of the heparanase inhibitor PI-88 in patients with advanced 
melanoma. Invest New Drugs, Vol. 26, No. 1, pp. 89-94 
Liotta, L., & Kohn, E.C. (2001). The microenvironment of the tumour-host interface. Nature, 
No. 411, pp. 375–9  
Liu, G., Zhang, F., Lee, J., & Dong, Z. (2005). Selective induction of interleukin-8 expression 
in metastatic melanoma cells by transforming growth factor-ǃ1. Cytokine, Vol. 31, 
No. 3, pp. 241–249 
Lu L., Payvandi, F., Wu, L., Zhang, L.H., Hariri, R.J., Man, H.W., Chen, R.S., Muller, G.W., 
Hughes, C.C., Stirling, D.I., Schafer, P.H., & Bartlett, J.B. (2009). The anti-cancer 
drug Lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory 
effects on endothelial cell function in normoxic and hypoxic conditions. 
Microvascular Research, Vol. 77, No. 2, pp. 78–86 
Luttun, A., Autiero, M., Tjwa, M., & Carmeliet, P. (2004). Genetic dissection of tumour 
angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochimica et 
Biophysica Acta, Vol. 1654, No. 1, pp. 79–94 
Lutzky, J., Weber, R., Nunez, Y., Gillett, M., & Spitler, L. (2009). A phase 1 study of 
granulocyte macrophage colony-stimulating factor (sargramostim) and escalating 
doses of Thalidomide in patients with high-risk malignant melanoma. Journal of 
Immunotherapy, Vol. 32, No. 1, pp. 79–85 
Mahler, D.A., Huang, S., Tabrizi, M., & Bell, G.M. (2004). Efficacy and safety of a monoclonal 
antibody recognizing interleukin-8 in COPD: a pilot study. Chest, Vol. 126, No. 3, 
pp. 926–934 
Maniotis, A.J., Folberg, R., Hess, A., Seftor, E.A., Gardner, L.M., Pe'er, J., Trent, J.M., Meltzer, 
P.S., & Hendrix, M.J. (1999). Vascular channel formation by human melanoma cells 
in vivo and vitro: vasculogenic mimicry. Am J Pathol., Vol. 155, pp. 739-752 
Marcoval, J., Moreno, A., Graells, J., Vidal, A., Escribà, J.M., Garcia-Ramírez, M., & Fabra, A. 
(1997). Angiogenesis and malignant melanoma. Angiogenesis is related to the 
development of vertical (tumourigenic) growth phase. Journal of Cutaneous 
Pathology, Vol. 24, No. 4, pp. 212–218 
Margolin, K., Atkins, B., Thompson, A., Ernstoff, S., Weber, J., Flaherty, L., Clark, I., Weiss, 
G., Sosman, J., II Smith, W., Dutcher, P., Gollob, J., Longmate, J., & Johnson, D. 
(2002). Temozolomide and whole brain irradiation in melanoma metastatic to the 
brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol., Vol. 
128, pp. 214-218 
Melnikova, V.O., & Bar-Eli, M. (2006). Bioimmunotherapy for melanoma using fully human 
antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Research, Vol. 19, No. 5, 
pp. 395–405 
Mignatti, P., & Rifkin, D.B. (1993). Biology and biochemistry of proteinases in tumour 
invasion. Physiol. Rev., No. 73, pp. 161–195 
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
331 
Mihm, Jr M., Clark, Jr W., & Reed, R. (1975). The clinical diagnosis of malignant melanoma. 
Semin. Oncol., No. 2, pp. 105-118 
Mita M.M., Rowinsky, E.K., Forero, L., Eckhart, S.G., Izbicka, E., Weiss, G.R., Beeram, M., 
Mita, A.C., de Bono, J.S., Tolcher, A.W., Hammond, L.A., Simmons, P., Berg, K., 
Takimoto, C., & Patnaik, A. (2007). A phase II, pharmacokinetic, and biologic study 
of semaxanib and Thalidomide in patients with metastatic melanoma. Cancer 
Chemotherapy and Pharmacology, Vol. 59, no. 2, pp. 165–174 
Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G., & 
Piulats, J. (2000). In vivo therapy of malignant melanoma by means of antagonists 
of ǂv integrins. International Journal of Cancer, Vol. 87, No. 5, pp. 716–723 
Mueller, M.B. (1996). Different roles for plasminogen activators and metalloproteinases 
inmelanomametastasis. Current Topics in Microbiology and Immunology, Vol. 213, pp. 
65–80 
Nikkola, J., Vihinen, P., Vuoristo, M.-S., Kellokumpu-Lehtinen, P., Kahari, V.M., & 
Pyrh¨onen, S. (2005). High serum levels of matrix metalloproteinase-9 and matrix 
metalloproteinase-1 are associated with rapid progression in patients with 
metastatic melanoma. Clinical Cancer Research, Vol. 11, No. 14, pp. 5158–5166 
Norrby, K., & Woolley, D. (1993). Role of mast cells in mitogenesis and angiogenesis in 
normal tissue and tumour tissue. Adv. Biosci., No. 89, pp. 71–115 
Odorisio, T., Cianfarani, F., Failla, C.M., & Zambruno, G.  (2006). The placenta growth factor 
in skin angiogenesis. Journal of Dermatological Science, Vol. 41, No. 1, pp. 11–19 
Ott, P.A., Chang, J.L., Oratz, R., Jones, A., Farrell, K., Muggia, F., & Pavlick, A.C. (2009). 
Phase II trial of Dacarbazine and Thalidomide for the treatment of metastatic 
melanoma. Chemotherapy, Vol. 55, No. 4, pp. 221–227  
Park, C.C., Bissell, M.J., & Barcellos-Hoff, M.H. (2000). The influence of the 
microenvironment on the malignant phenotype. Mol Med Today, No. 6, pp. 324–9  
Pavlaki, M., & Zucker, S. (2003). Matrix metalloproteinase inhibitors (MMPIs): the beginning 
of phase I or the termination of phase III clinical trials. Cancer and Metastasis 
Reviews, Vol. 22, No. 2-3, pp. 177–203 
Pawlak, W.Z., & Legha, S.S. (2004). Phase II study of Thalidomide in patients with 
metastatic melanoma. Melanoma Res, Vol. 14, pp. 57-62 
Perez, D.G., Suman, V.J., Fitch, T.R., Amatruda, T. 3rd, Morton, R.F., Jilani, S.Z., 
Constantinou, C.L., Egner, J.R., Kottschade, L.A., & Markovic, S.N. (2009). Phase 2 
trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with 
unresectable stage IV melanoma: a North Central Cancer Treatment Group study, 
N047A. Cancer, Vol. 115, No. 1, pp. 119–127 
Peterson, A.C., Swiger,S., Stadler, S.M., Medved, M., Karczmar, G., & Gajewski, T.F.(2004). 
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. 
Clinical Cancer Research, Vol. 10, No. 12, part 1, pp. 4048–4054 
Qi, J., Nakayama, K., Gaitonde, S., Goydos, J.S., Krajewski, S., Eroshkin, A., Bar-Sagi, D., 
Bowtell, D., & Ronai, Z.  (2008). The ubiquitin ligase Siah2 regulates tumourigenesis 
and metastasis by HIF-dependent and -independent pathways. Proc Natl Acad Sci 
USA, No. 105, pp. 16713–16718 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
332 
Qu, B., Guo, L., Ma, J., & Lv, Y. (2010). Antiangiogenesis therapy might have the unintended 
effect of promoting tumour metastasis by increasing an alternative circulatory 
system. Medical Hypotheses, Vol. 74, No. 2, pp. 360–361 
Quirt, I., Bodurth, A., Lohmann, R., Rusthoven, J., Belanger, K., Young, V., Wainman, N., 
Stewar, W., Eisenhauer, E.; National Cancer Institute of Canada Clinical Trials 
Group. (2002). Phase II study of marimastat (BB-2516) in malignant melanoma: a 
clinical and tumour biopsy study of the National Cancer Institute of Canada 
Clinical Trials Group. Investigational New Drugs, Vol. 20, No. 4, pp. 431–437 
Quirt, I., Verma, S., Petrella, T., Bak, K., & Charette,M. (2007). Temozolomide for the 
treatment of metastatic melanoma: a systematic review. Oncologist, Vol. 12, No. 9, 
pp. 1114–1123 
Reiriz, A.B., Richter, M.F., Fernandes, S., Cancela, A.I., Costa, T.D., DiLeone, L.P., & 
Schwartsmann, G. (2004). Phase II study of Thalidomide in patients with metastatic 
malignant melanoma. Melanoma Res, Vol. 14, pp. 527-31 
Risau, W., Sariola, H., Zerwes, H.G., Sasse, J., Ekblom, P., Kemler, R., & Doetschman, T. 
(1988). Vasculogenesis and angiogenesis in embryonic stem-cell-derived embryoid 
bodies. Development, No. 102, pp. 471-478 
Roy, R., Yang, J., & Moses, M.A. (2009). Matrix metalloproteinases as novel biomarkers and 
potential therapeutic targets in human cancer. Journal of Clinical Oncology, Vol. 27, 
No. 31, pp. 5287–5297 
Rudek, M.A., Figg, W.D., Dyer, V., Dahut, W., Turner, M.L., Steinberg, S.M., Liewehr, D.J., 
Kohler, D.R., Pluda, J.M., & Reed, E. (2001). Phase I clinical trial of oral COL-3, a 
matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. 
Journal of Clinical Oncology, Vol. 19, No. 2, pp. 584–592 
Salven, P., Heikkil¨a, P., & Joensuu, H.  (1997). Enhanced expression of vascular endothelial 
growth factor in metastatic melanoma. British Journal of Cancer, Vol. 76, No. 7, pp. 
930–934 
Schicher, N., Paulitschke, V., Swoboda, A., Kunstfeld, R., Loewe, R., Pilarski, P., 
Pehamberger, H., Hoeller, C. (2009). Erlotinib and bevacizumab have synergistic 
activity against melanoma. Clinical Cancer Research, Vol. 15, No. 10, pp. 3495–3502 
Schnaeker, E.-M., Ossig, R., Ludwig, T., Dreier, R., Oberleithner, H., Wilhelmi, M., & 
Schneider, S.W. (2004). Microtubule-dependent matrix metalloproteinase-2/matrix 
metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. 
Cancer Research, Vol. 64, No. 24, pp. 8924–8931 
Singhal, S., & Mehta, J. (2002). Thalidomide in cancer. Biomedicine and Pharmacotherapy, Vol. 
56, No. 1, pp. 4–12 
Son, M.J., Kim, J.S., Kim, M.H., Song, H.S., Kim, J.T., Kim, H., Shin, T., Jeon, H.J., Lee, D.S., 
Park, S.Y., Kim, Y.J., Kim, J.H., & Nam, D.H. (2006). Combination treatment with 
Temozolomide and Thalidomide inhibits tumour growth and angiogenesis in an 
orthotopic glioma model. Int J Oncol., Vol. 28, No. 1, pp. 53-59 
Srivastava, A., Laidler, P., Davies, R.P., Horgan, K., & Hughes, L.E. (1988). The prognostic 
significance of tumour vascularity in Dermatology Research and Practice 5 
intermediate-thickness (0.76–4.0mm thick) skin melanoma. A quantitative 
histologic study. American Journal of Pathology, Vol. 133, No. 2, pp. 419–423 
www.intechopen.com
 Role of Angiogenesis and Microenvironment in Melanoma Progression 
 
333 
Srivastava, A., Hughes, L.E., Woodcock, J.P., & Laidler, P. (1989). Vascularity in cutaneous 
melanoma detected by Doppler sonography and histology: correlation with tumour 
behaviour. British Journal of Cancer, Vol. 59, No. 1, pp. 89–91 
Stack, M.S. & Johnson, D.A. (1994). Human mast cell tryptase activates single-chain urinary-
type plasminogen activator (pro-urokinase). J. Biol. Chem., No. 269, pp. 9416–9419 
Starkey, J.R., Crowle, P.K., & Taubenberg, S. (1988). Mast cell-deficient W/Wv mice exhibit a 
decreased rate of tumour angiogenesis. Int. J. Cancer, No. 42, pp. 48–52 
Stasi, R., & Amadori, S. (2002). The role of angiogenesis in hematologic Malignancies. J of 
Hematotherapy & stem cell research, No. 11, pp. 49-68 
Streit, M., & Detmar, M. (2003). Angiogenesis, lymphangiogenesis, and melanoma 
metastasis. Oncogene, No. 22, pp. 3172-3179 
Suhr, F., Brixius, K., & Bloch, W. (2009). Angiogenic and vascular modulation by 
extracellular matrix cleavage products. Current Pharmaceutical Design, Vol. 15, No. 
4, pp. 389–410 
Toth, T., Toth-Jakatics, R., Jimi, S., Takebayashi, S., & Kawamoto, N. (2000). Cutaneous 
malignant melanoma: correlation between neovascularization and peritumour 
accumulation of mast cells overexpressing vascular endothelial growth factor. Hum. 
Pathol, No. 31, pp. 955–960 
Vaishampayan, U.N., Heilbrun, L.K., Marsack,C., Smith, D.W., & Flaherty, L.E. (2007). Phase 
II trial of pegylated interferon and Thalidomide in malignant metastatic melanoma. 
Anti-Cancer Drugs, Vol. 18, No. 10, pp. 1221–1226 
Varker, K.A., Biber, J.E., Kefauver, C., Jensen, R., Lehman, A., Young, D., Wu, H., Lesinski, 
G.B., Kendra, K., Chen, H.X., Walker, M.J., & Carson, W.E. 3rd. (2007). A 
randomized phase 2 trial of bevacizumab with or without daily low-dose interferon 
alfa-2b in metastatic malignant melanoma. Annals of Surgical Oncology, Vol. 14, No. 
8, pp. 2367–2376 
Vásquez, L.M., Somani, S., Altomare, F., & Simpson, E.R., (2009). Intracameral bevacizumab 
in the treatment of neovascular glaucoma and exudative retinal detachment after 
brachytherapy in choroidal melanoma. Canadian Journal of Ophthalmology, Vol. 44, 
No. 1, pp. 106–107 
Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Rev., No. 26, pp. 225–239. 
Wani, A.A., Jafarnejad, S.M., Zhou, J., & Li, G. (2011). Integrin-linked kinase regulates 
melanoma angiogenesis by activating NF-κB/interleukin-6 signalling pathway. 
Oncogene, PMID 21278793  
Warren, B.A., & Shubik, P. (1966). The growth of the blood supply to melanoma transplants 
in the hamster cheek pouch. Lab. Invest., No. 15, pp. 464-478 
Wojtowicz-Praga, S., Low, J., Marshall, J., Ness, E., Dickson, R., Barter, J., Sale, M., McCann, 
P., Moore, J., Cole, A., & Hawkins, M.J. (1996). Phase I trial of a novel matrix 
metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. 
Investigational New Drugs, Vol. 14, No. 2, pp. 193–202 
Wojtowicz-Praga, S., Torri, J., Johnson, M., Steen, V., Marshall, J., Ness, E., Dickson, R., Sale, 
M., Rasmussen, H.S., Chiodo, T.A., & Hawkins, M.J. (1998). Phase I trial of 
Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to 
www.intechopen.com
 Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
334 
patients with advanced lung cancer. Journal of Clinical Oncology, Vol. 16, No. 6, pp. 
2150–2156  
Yang, M.H., & Wu, K.J.  (2008). TWIST activation by hypoxia inducible factor-1 (HIF-1): 
implications in metastasis and development. Cell Cycle, No. 7, pp. 2090–2096 
Zeldis, J.B., Knight, R., Hussein, M., Chopra, R., Muller, G., & Ann, N.Y. (2011) A review of 
the history, properties, and use of the immunomodulatory compound 
Lenalidomide. Acad Sci., Vol. 1222, No. 1, pp. 76-82 
Zhang, S., Li, M., Gu, Y., Liu, Z., Xu, S., Cui, Y., & Sun, B. (2008). Thalidomide influences 
growth and vasculogenic mimicry channel formation in melanoma. Journal of 
Experimental and Clinical Cancer Research, Vol. 27, No. 1, article 60 
www.intechopen.com
Research on Melanoma - A Glimpse into Current Directions and
Future Trends
Edited by Prof. Mandi Murph
ISBN 978-953-307-293-7
Hard cover, 414 pages
Publisher InTech
Published online 12, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book Research on Melanoma: A Glimpse into Current Directions and Future Trends, is divided into
sections to represent the most cutting-edge topics in melanoma from around the world. The emerging
epigenetics of disease, novel therapeutics under development and the molecular signaling aberrations are
explained in detail. Since there are a number of areas in which unknowns exist surrounding the complex
development of melanoma and its response to therapy, this book illuminates and comprehensively discusses
such aspects. It is relevant for teaching the novice researcher who wants to initiate projects in melanoma and
the more senior researcher seeking to polish their existing knowledge in this area. Many chapters include
visuals and illustrations designed to easily guide the reader through the ideas presented.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Roberto Ria, Antonia Reale and Angelo Vacca (2011). Role of Angiogenesis and Microenvironment in
Melanoma Progression, Research on Melanoma - A Glimpse into Current Directions and Future Trends, Prof.
Mandi Murph (Ed.), ISBN: 978-953-307-293-7, InTech, Available from:
http://www.intechopen.com/books/research-on-melanoma-a-glimpse-into-current-directions-and-future-
trends/role-of-angiogenesis-and-microenvironment-in-melanoma-progression
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
